TLDR:
- Sands Capital has closed its third life sciences fund at $555 million.
- The fund will focus on private therapeutics, diagnostics, medical devices, and life sciences tools businesses.
In a recent development, Sands Capital has successfully wrapped up its third life sciences fund, known as Sands Capital Life Sciences Pulse Fund III, with a total capital commitment of $555 million. The fund is set to target private companies in the field of therapeutics, diagnostics, medical devices, and life sciences tools. This fund aims to support innovative businesses in the life sciences sector and drive growth and advancements in healthcare technologies.
This fund closure represents Sands Capital’s continued commitment to investing in the life sciences industry and supporting companies that are working towards improving patient outcomes and healthcare innovation. With a strong focus on delivering value to both investors and the broader healthcare ecosystem, Sands Capital Life Sciences Pulse Fund III is poised to make a significant impact in the field of life sciences.
